Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
暂无分享,去创建一个
[1] D. Welch,et al. Genetic Basis of Human Breast Cancer Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.
[2] V. Sementchenko,et al. The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. , 2003, Anticancer research.
[3] M. Szyf,et al. Regulation of DNA Methylation in Human Breast Cancer , 2002, The Journal of Biological Chemistry.
[4] B. Clurman,et al. p53 and p21 Form an Inducible Barrier that Protects Cells against Cyclin E-cdk2 Deregulation , 2002, Current Biology.
[5] F. Rösel,et al. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. , 2002, Biochemical and biophysical research communications.
[6] M. Duffy. Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .
[7] V. Sementchenko,et al. Ets1 Is an Effector of the Transforming Growth Factor β (TGF-β) Signaling Pathway and an Antagonist of the Profibrotic Effects of TGF-β* , 2002, The Journal of Biological Chemistry.
[8] Hong Duan,et al. Role for DNA methylation in the control of cell type–specific maspin expression , 2002, Nature Genetics.
[9] Steven F. Dowdy,et al. Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .
[10] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[11] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[12] Steven F Dowdy,et al. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. , 2002, Current opinion in genetics & development.
[13] C. Paweletz,et al. New approaches to proteomic analysis of breast cancer , 2001, Proteomics.
[14] J. Kreidberg,et al. Urokinase Receptors Promote β1 Integrin Function through Interactions with Integrin α3β1 , 2001 .
[15] M. Ranson,et al. The topology of plasminogen binding and activation on the surface of human breast cancer cells , 2001, British Journal of Cancer.
[16] J. Marks,et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. , 2001, Cancer research.
[17] M. Duffy,et al. Biochemical markers in breast cancer: which ones are clinically useful? , 2001, Clinical biochemistry.
[18] S. Ethier,et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. , 2001, Cancer research.
[19] V. Sementchenko,et al. Ets target genes: past, present and future , 2000, Oncogene.
[20] R. Sager,et al. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.
[21] Duanduan Ma,et al. Exit from G1 and S Phase of the Cell Cycle Is Regulated by Repressor Complexes Containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF , 2000, Cell.
[22] T. Kuroki,et al. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. , 2000, The Journal of biological chemistry.
[23] M. Hendrix,et al. Epigenetic silencing of maspin gene expression in human breast cancers , 2000, International journal of cancer.
[24] T. Miki,et al. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. , 2000, Cancer research.
[25] P. Andreasen,et al. The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.
[26] T. Libermann,et al. PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.
[27] M. Nozaki,et al. Cloning and expression of the mouse Pse gene encoding a novel Ets family member. , 2000, Gene.
[28] T. Kuroki,et al. Involvement of Protein Kinase C d ( PKC d ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells , 2000 .
[29] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[30] J. Sipley,et al. Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.
[31] S. Rabbani,et al. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of DNA methylation. , 1999, International journal of cancer.
[32] B. Kacinski,et al. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. , 1998, Cancer research.
[33] K. Kinzler,et al. A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Sager,et al. Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] Wen-Lin Kuo,et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.
[36] R. Sager,et al. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[37] B. Vandenbunder,et al. PEA3 transactivates vimentin promoter in mammary epithelial and tumor cells. , 1996, Oncogene.
[38] M. Hendrix,et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.
[39] J. Marks,et al. p53 alterations in all stages of breast cancer , 1991, Journal of surgical oncology.
[40] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[41] R. Lidereau,et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.